Keytruda takes on deadly thyroid cancer in tiny trial
Disease control
Ongoing
This Phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in 12 people with advanced anaplastic thyroid cancer, a rare and fast-growing cancer with no standard cure. Participants receive the drug every three weeks to see if tumors shrink or stop growing. The study …
Phase 2 • Sponsor: Saad A Khan • Aim: Disease control
Last updated Sep 10, 2026 05:00 UTC